Robert B Laprairie Selected Research

3- (2- nitro- 1- phenylethyl)- 2- phenyl- 1H- indole

1/2021	Effects of the cannabinoid receptor 1 positive allosteric modulator GAT211 and acute MK-801 on visual attention and impulsivity in rats assessed using the five-choice serial reaction time task.
1/2020	Application of Fluorine- and Nitrogen-Walk Approaches: Defining the Structural and Functional Diversity of 2-Phenylindole Class of Cannabinoid 1 Receptor Positive Allosteric Modulators.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Robert B Laprairie Research Topics

Disease

7	Huntington Disease (Huntington's Disease) 01/2019 - 09/2013
4	Pain (Aches) 01/2021 - 01/2017
3	Absence Epilepsy (Childhood Absence Epilepsy) 06/2022 - 01/2021
3	Epilepsy (Aura) 01/2022 - 01/2020
3	Inflammation (Inflammations) 01/2020 - 10/2016
2	Glaucoma 11/2021 - 01/2021
2	Schizophrenia (Dementia Praecox) 04/2021 - 01/2021
2	Substance-Related Disorders (Drug Abuse) 01/2020 - 10/2016
2	Obesity 11/2019 - 10/2016
1	Neoplasms (Cancer) 05/2022
1	Neuroblastoma 05/2022
1	Sleep Initiation and Maintenance Disorders (Insomnia) 01/2021
1	Catalepsy 01/2021
1	Seizures (Absence Seizure) 01/2021
1	Psychotic Disorders (Schizoaffective Disorder) 01/2021
1	Drug Resistant Epilepsy 01/2020
1	Post-Traumatic Stress Disorders (Post Traumatic Stress Disorder) 01/2020
1	Hypothermia 01/2019
1	Chorea (Rheumatic Chorea) 01/2018

Drug/Important Bio-Agent (IBA)

10	Cannabinoid Receptors (Cannabinoid Receptor)IBA 06/2022 - 09/2013
10	CannabinoidsIBA 05/2022 - 09/2013
8	EndocannabinoidsIBA 01/2021 - 02/2014
2	Biological ProductsIBA 05/2022 - 01/2021
2	GTP-Binding Proteins (G-Protein)IBA 01/2021 - 01/2017
2	CannabidiolIBA 01/2021 - 01/2020
2	Pharmaceutical PreparationsIBA 01/2021 - 01/2017
2	Neurotransmitter Agents (Neurotransmitter)IBA 01/2021 - 01/2020
2	3- (2- nitro- 1- phenylethyl)- 2- phenyl- 1H- indoleIBA 01/2021 - 01/2020
1	CB2 Cannabinoid ReceptorIBA 05/2022
1	2-phenylindoleIBA 11/2021
1	Antipsychotic Agents (Antipsychotics)IBA 04/2021
1	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 04/2021
1	3- (2- hydroxy- 4- (1,1- dimethylheptyl)phenyl)- 4- (3- hydroxypropyl)cyclohexanolIBA 01/2021
1	Dizocilpine Maleate (Dizocilpine)IBA 01/2021
1	Glutamic Acid (Glutamate)FDA Link 01/2021
1	OrexinsIBA 01/2021
1	EnzymesIBA 01/2020
1	Anticonvulsants (Antiepileptic Drugs)IBA 01/2020
1	Opioid Analgesics (Opioids)IBA 01/2020
1	Analgesics (Analgesic Drugs)IBA 01/2020
1	Indomethacin (Indometacin)FDA LinkGeneric 01/2019
1	CB1 Cannabinoid Receptor (CB1 Receptor)IBA 01/2018
1	LigandsIBA 01/2018
1	Dopamine (Intropin)FDA LinkGeneric 02/2015
1	amsonic acid (DAS)IBA 02/2015
1	CytokinesIBA 02/2014
1	Huntingtin ProteinIBA 09/2013

Therapy/Procedure

2	Therapeutics 01/2021 - 01/2020
1	Pain Management 10/2016